Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences

NCT05819593 | Not Yet Recruiting

• 1 other identifier: 80865259
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in anaplastic thyroid cancer clinical research, as well as the reasons for withdrawal or discontinuation. Insights gained from this study will ultimately benefit those with anaplastic thyroid cancer who may be invited to participate in clinical research in the years to come.

Conditions

Anaplastic Thyroid Cancer

Keywords

anaplastic thyroid cancer

Outcome Measures

Primary Outcomes (2)

• Number of anaplastic thyroid cancer patients who decide to enroll in a clinical study

  3 months

• Rate of anaplastic thyroid cancer patients who remain in a clinical study to completion

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with anaplastic thyroid cancer who are actively considering participating in an observational clinical study, but have not yet completed enrollment and randomization.

You may qualify if:

• Diagnosed with anaplastic thyroid cancer
• Willing to comply with all study related procedures and assessments
• Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol

You may not qualify if:

• No documented diagnosis of anaplastic thyroid cancer
• Any serious and/or unstable pre-existing medical disorders
• Pregnant or lactating woman

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Related Publications (3)

• Al-Jundi M, Thakur S, Gubbi S, Klubo-Gwiezdzinska J. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review. Cancers (Basel). 2020 Jul 29;12(8):2104. doi: 10.3390/cancers12082104.

  PMID: 32751138 BACKGROUND

• Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018 Oct 23;17(1):154. doi: 10.1186/s12943-018-0903-0.

  PMID: 30352606 BACKGROUND

• Ljubas J, Ovesen T, Rusan M. A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer. Cancers (Basel). 2019 Jul 4;11(7):943. doi: 10.3390/cancers11070943.

  PMID: 31277524 BACKGROUND

MeSH Terms

Conditions

Thyroid Carcinoma, Anaplastic

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

4159004227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 6, 2023
• First Posted: April 19, 2023
• Study Start: May 1, 2024
• Primary Completion: May 1, 2025
• Study Completion: May 1, 2026
• Last Updated: April 19, 2023

Record last verified: 2023-04